Manager TitleAgeSince
President 42 -
Corporate Secretary - -
Treasurer 60 -
Director TitleAgeSince
Director/Board Member 42 -
Date Insider Type Main position Quantity % Market Cap.
28/07/20Tender

Chief Executive Officer

21,978 0.3026%
28/07/20Tender

Chief Financial Officer

6,239 0.0859%
28/07/20Tender

Chairman

2,135 0.0294%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-10.93% - - 16.07M
-1.14%-2.43%+53.72%+159.07% 1,070B
-1.41%+0.32%+66.23%+60.48% 624B
-2.42%+0.18%+34.59%+85.62% 450B
-0.38%+0.53%+31.00%+25.82% 328B
+1.96%+1.94%+40.67%+42.18% 292B
+1.09%-0.13%+29.52%+48.89% 284B
+2.37%+4.51%-25.48%-38.77% 217B
-2.06%+1.63%+22.87%+64.34% 198B
-1.26%+2.60%+15.98%+70.00% 161B
Average +0.97%+1.07%+29.90%+57.51% 402.71B
Weighted average by Cap. +1.33%+0.77%+40.39%+81.88%
Logo Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.
Employees
-